Stock comparison
Apellis Pharmaceuticals
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
APLS
Apellis Pharmaceuticals
Market cap
$5.25B
Sector
Healthcare
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
Overall winner
Apellis Pharmaceuticals APLS
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | APLS | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 58C | 72B | RMD |
| Benjamin Graham | 79D | 75B | APLS |
| Philip Fisher | 71C | 75B | RMD |
| Peter Lynch | 81C | 58C | APLS |
| Joel Greenblatt | 63C | 47D | APLS |
| Charlie Munger | 67D | 69B | RMD |
| Terry Smith | 65B | 73B | RMD |
Side-by-side metrics
| Metric | APLS | RMD |
|---|---|---|
| Market cap | $5.25B | $30.18B |
| P/E (TTM) | 38.8x | 19.6x |
| EV/EBIT | 96.0x | 17.1x |
| ROIC (TTM) | 18.11% | 19.63% |
| Gross margin | 90.12% | 61.69% |
| Net margin | 12.06% | 27.44% |
| Revenue CAGR 5y | 97.06% | 12.64% |
| EPS CAGR 5y | - | 30.73% |
| Debt / Equity | 1.1x | 0.1x |
| Dividend yield | 0.0% | 1.14% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
APLS leads on
- Revenue CAGR 5y97.06%vs 12.64%+87%
- Gross margin90.12%vs 61.69%+32%
RMD leads on
- Dividend yield1.14%vs 0.0%+100%
- Debt / Equity0.1xvs 1.1x+89%
- Market cap$30.18Bvs $5.25B+83%
- EV/EBIT17.1xvs 96.0x+82%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.